Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

21. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations

,EasternCooperativeOncologyGroup; EGFR,epidermalgrowthfactorreceptor;IHC,immunohistochemistry;N/A, notapplicable;NSCLC, non–small-cell lung cancer; PD-L1, programmed death ligand 1; PS, performance status; SCC, squamous cell carcinoma; Teff, T effector; TPS, tumor proportion score. Journal of Clinical Oncology 7 Systemic Therapy for Stage IV NSCLC Guideline UpdatePatients with cancers with sensitizing EGFR or ALK alter- ations were excluded from the trial. The study’s primary outcomeswereOSandPFS.OSintheinterventionarmwas (...) Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Bryan J. Schneider,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson,MD

2020 Cancer Care Ontario

22. Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Guideline Update Guideline Question What systemic therapy treatment options should be offered to patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations, depending on the subtype of the patient’s cancer? Target Population Patients with stage IV NSCLC without driver alterations in epidermal growth factor receptor ( EGFR ) or anaplastic lymphoma kinase ( ALK ) (with known EGFR and ALK ) status (plus programmed death ligand 1 (PD-L1) tumor proportion score (TPS) test results (...) Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03022 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Therapy for Stage IV Non

2020 American Society of Clinical Oncology Guidelines

23. Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) Atezolizumab with carboplatin and nab- paclitaxel for untreated advanced non-squamous non- small-cell lung cancer (terminated appraisal) T echnology appraisal guidance Published: 15 January 2020 www.nice.org.uk/guidance/ta618 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents (...) Contents Advice 3 Information 3 Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small- cell lung cancer (terminated appraisal) (TA618) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

24. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

, multicentre, double-blind, randomised, controlled, phase 3 trial. Eligible patients were aged at least 18 years, had a WHO performance status of 0 or 1, with histologically or cytologically documented stage III, unresectable non-small-cell lung cancer, for which they had received at least two cycles of platinum-based chemoradiotherapy, with no disease progression after this treatment. We randomly assigned patients (2:1) using an interactive voice response system and a blocked design (block size=3 (...) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Patient-reported Outcomes With Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small-Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed

2020 EvidenceUpdates

25. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several (...) than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 38 (2), 115-123 2020 Jan 10 Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates

26. Hand-held Fan Airflow Stimulation Relieves Dyspnea in Lung Cancer Patients. Full Text available with Trip Pro

Hand-held Fan Airflow Stimulation Relieves Dyspnea in Lung Cancer Patients. The main symptom of lung cancer is dyspnea which can lead to depression, anxiety, limited independent activities, and decreased quality of life. The purpose of this study was to identify the effect of airflow stimulation from a hand-held fan as nonpharmacological palliative intervention on dyspnea in patients with lung cancer.This study used open, randomized, controlled, crossover trial design involved 21 participants (...) . Diaphragmatic breathing technique was used in control arm.Wilcoxon test result showed that airflow stimulation significantly influenced dyspnea scale (P = 0.003) and respiratory rate (RR) (P = 0.008). Combination of airflow stimulation and diaphragmatic breathing can lower both dyspnea scale and RR significantly (P < 0.0001).This combination can be applied on nonhypoxemic dyspneic lung cancer patients.

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

27. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

28. Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Thoren ? Volker Vervölgyi Keywords: dacomitinib, carcinoma – non-small-cell lung, benefit assessment, NCT01774721 Extract of dossier assessment A19-39 Version 1.0 Dacomitinib (non-small cell lung cancer) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 8 2.3 Research question 1: patients with the activating EGFR (...) It was assumed for the present therapeutic indication that the NSCLC patients have stage IIIB to IV disease (staging according to the International Association for the Study of Lung Cancer [IASLC], Union for International Cancer Control [UICC]), without medical indication for curative resection, radiotherapy or radiochemotherapy. In the present assessment, the following terms are used for the respective populations of the research questions: ? Research question 1: patients with the activating EGFR mutations

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

29. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008 (Abstract)

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008 The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy

2019 EvidenceUpdates

30. Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) - metastatic non-squamous non-small cell lung cancer (NSCLC) Published 09 December 2019 1 Statement of advice SMC2254 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation atezolizumab (Tecentriq®) is not recommended for use within NHSScotland. Indication under review: In combination with nab-paclitaxel and carboplatin for the first (...) -line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium

2019 Scottish Medicines Consortium

31. Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group Full Text available with Trip Pro

. Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lung cancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell).1568 participants were (...) randomised during 2007-2011 from 10 UK centres. 85.2% of those screened provided an adequate baseline sputum sample. There were 42 lung cancers among 785 screened individuals and 36 lung cancers among 783 controls. 54.8% (23 out of 42) of screened individuals versus 45.2% (14 out of 31) of controls with known staging were diagnosed with early-stage disease (one-sided p=0.24). Relative risk was 1.21 (95% CI 0.75-1.95) or 0.82 (95% CI 0.52-1.31) for early-stage or advanced cancers, respectively. Overall

2019 EvidenceUpdates

32. Atezolizumab (Tecentriq) - non-squamous non-small cell lung cancer (NSCLC)

Atezolizumab (Tecentriq) - non-squamous non-small cell lung cancer (NSCLC) 1 Published 11 November 2019 1 SMC2208 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq®) Roche Products Ltd 04 October 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under (...) the end of life medicine process: atezolizumab (Tecentriq ® ) is not recommended for use within NHSScotland. Indication under review: In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin

2019 Scottish Medicines Consortium

33. Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC)

Dacomitinib (Vizimpro) - non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September

2019 Health Canada - Drug and Health Product Register

34. Recommendations for Prophylactic Cranial Irradiation and Consolidative Radiation for Patients with Small Cell Lung Cancer: Endorsement of the 2019 National Institute for Health and Care Excellence Guidance

Institute for Health and Care Excellence Guidance M. Taremi, E.T. Vella, S. Cheng, P.M. Ellis, R. Goffin, A. Louie, R. MacRae, Y.C. Ung, and the Lung Cancer Disease Site Group Report Date: November 11, 2019 This document describes the CCO-Lung Cancer Disease Site Group endorsement of the recommendations for prophylactic cranial irradiation and consolidative radiation for patients with small cell lung cancer from © NICE [2019] Lung cancer: diagnosis and management. The original publication is available (...) : Guideline Endorsement ENDORSEMENT The Lung Cancer Disease Site Group of Cancer Care Ontario (CCO) endorses the following clinical recommendations for prophylactic cranial irradiation and consolidative radiation for patients with small cell lung cancer (SCLC) found in the Lung cancer: diagnosis and management guideline, published by the National Institute for Health and Care Excellence (NICE) [1]. They are reprinted with the permission of NICE. 1 RECOMMENDATIONS Limited-stage disease SCLC Offer

2019 Cancer Care Ontario

35. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. (Abstract)

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Most patients with small-cell lung cancer (SCLC) have extensive-stage disease at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated clinical activity in extensive-stage SCLC (ES-SCLC). The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination (...) with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC.This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries. Eligible patients were adults with untreated ES-SCLC, with WHO performance status 0 or 1 and measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1. Patients were randomly assigned (in a 1:1:1 ratio) to durvalumab plus platinum-etoposide; durvalumab plus tremelimumab plus platinum

2019 Lancet

36. Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details | CADTH.ca Find the information you need Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details Project Number pCODR 10183 Brand Name Lorbrena Generic Name Lorlatinib Tumour Type Lung Indication Non-Small Cell Lung Cancer (NSCLC) Funding Request For the treatment of adult patients with anaplastic (...) lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib. Review Status Under Review Pre Noc Submission No NOC Date Manufacturer Pfizer Canada ULC Sponsor Pfizer Canada ULC Submission Date June 11, 2019 Submission Deemed Complete June 25, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ June 25, 2019 Check-point meeting

2019 CADTH - Pan Canadian Oncology Drug Review

37. Tecentriq for Small Cell Lung Cancer – Details

Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details Project Number pCODR 10156 Brand Name Tecentriq Generic Name Atezolizumab Strength 60 mg/mL Tumour Type Lung Indication Small Cell Lung Cancer (SCLC) Funding Request For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC

2019 CADTH - Pan Canadian Oncology Drug Review

38. Metastatic Non-Small-Cell Lung Cancer

for 80%–90% of lung cancers, while small cell lung cancer (SCLC) has been decreasing in frequency in many countries over the past two decades [4]. During the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men, while in women, both SCC and adenocarcinoma are still increasing [5 (...) epidemiological data have resulted in ‘non-smoking-associated lung cancer’ being considered a distinct disease entity, where specific molecular and genetic tumour characteristics have been identified [14]. Updated version published 18 September 2019 by the ESMO Guidelines Committee © European Society for Medical Oncology 2019. All rights reserved. 2 Use of non-cigarette tobacco products such as cigars and pipes has been increasing. A pooled analysis highlighted the increased risk, particularly for lung

2019 European Society for Medical Oncology

39. Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive Drug Approval Package: ROZLYTREK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ROZLYTREK Company: Genentech Application Number: 212725, 212726 Approval Date: 08/15/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

40. Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details

Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour (...) Type Gastrointestinal / Lung Indication Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre

2019 CADTH - Pan Canadian Oncology Drug Review